Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal injection versus medical treatment for acute central serous chorioretinopathy
PACTR202204601902304Phase 3Unknown
- Sponsor
- Suez Canal University Hospital
- Start
- Nov 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of spironolactone, ranibizumab and aflibercept in Central Serous Chorioretinopathy (CSCR) (3 arms), sponsored by Suez Canal University Hospital. Primary endpoint: Visual recovery. Status: unknown.
02
Drugs
spironolactoneranibizumabaflibercept
03
Conditions
Central Serous Chorioretinopathy (CSCR)
Beyond the preview
Go deeper on PACTR202204601902304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202204601902304.